ReviewCells2022
Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- The "Cold Tumor" to "Hot Tumor" transformation strategy for triple-negative breast cancer: from mechanism to clinical translation.Molecular and cellular biochemistry · 2026Review
- MASLD Under the Umbrella of the Microbiota: A Narrative Review on Ecological Risk and Functional Transmissibility.Journal of clinical medicine · 2026Review
- Review
- Analysis of subgingival microbial community structure in MAFLD patients with periodontitis.Clinical oral investigations · 2025Article
- The Association BetweenNutrients · 2025Article
- Effects of dietary live microbes intake on a newly proposed classification system for steatotic liver disease.Scientific reports · 2025Article
- Interaction mechanism and intervention strategy between metabolic dysfunction-associated steatotic liver disease and intestinal microbiota.Frontiers in microbiology · 2025Review
- Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease.Frontiers in molecular biosciences · 2025Article
- Understanding and treating diabetic foot ulcers: Insights into the role of cutaneous microbiota and innovative therapies.Skin health and disease · 2024Review
- Review
- Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect.World journal of gastroenterology · 2024Review
- The gut microbiota metabolite butyrate mitigates MPTP/MPPThe Kaohsiung journal of medical sciences · 2023Article
- Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.Medicina (Kaunas, Lithuania) · 2023Review
- Prevention of Metabolic Syndrome by Phytochemicals and Vitamin D.International journal of molecular sciences · 2023Review
- Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.International journal of molecular sciences · 2022Article
- Liver Fetuin-A at Initiation of Insulin Resistance.Metabolites · 2022Article
- Are elevated systemic bile acids involved in the pathophysiology of sarcopenia and liver injury following gastric bypass?Acta gastro-enterologica BelgicaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous studies show a modification of the gut microbiota in patients with obesity or diabetes. Animal studies have also shown a causal role of gut microbiota in liver metabolic disorders including steatosis whereas the human situation is less clear. Patients with metabolic dysfunction associated fatty liver disease (MAFLD) also have a modification in their gut microbiota composition but the changes are not fully characterized. The absence of consensus on a precise signature is probably due to disease heterogeneity, possible concomitant medications and different selection or evaluation criteria. The most consistent changes were increased relative abundance of Proteobacteria, Enterobacteriaceae and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.